Welcome to our dedicated page for Allarity Therapeutics SEC filings (Ticker: ALLR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Allarity Therapeutics, Inc. SEC filings document the company’s clinical-stage oncology business, capital structure, governance, and material-event disclosures. The filings identify Allarity’s Nasdaq-listed common stock and emerging growth company status, and include 8-K reports covering Regulation FD presentations, scientific and clinical updates for stenoparib and the DRP® companion diagnostic, intellectual-property developments, operating and financial results, and promissory-note financing.
Proxy materials describe annual meeting matters and stockholder voting procedures, while material definitive agreement filings and other current reports provide formal disclosure on financing arrangements, corporate progress, and regulatory or clinical communications tied to Allarity’s precision oncology programs.
Allarity Therapeutics, Inc. (ALLR) disclosed that Allarity Acquisition Corp., a newly formed special purpose acquisition company sponsored by ALLR Sponsor LLC, has publicly filed a Form S-1 for a proposed Nasdaq-listed IPO of its units. The base offering size is expected to be $100 million, increasing to $115 million if the underwriters’ over-allotment option is exercised in full.
ALLR Sponsor LLC, a wholly owned subsidiary of Allarity, is expected to own about 25.0% of Allarity Acquisition Corp.’s issued and outstanding ordinary shares after the offering, as described in the S-1. The SPAC may pursue a business combination in any industry or region, and has applied to list its units on Nasdaq under the symbol ALLNU. Allarity stated that this SPAC initiative does not change its expectation that existing working capital can fund operations into the summer of 2028.
Allarity Therapeutics, Inc. reported second-quarter 2026 results and development progress for stenoparib, its dual PARP/tankyrase inhibitor for cancer. For the quarter ended June 30, 2026, the company generated no revenue and recorded a net loss of $3.4 million, compared with $2.3 million a year earlier, as other income swung to a net expense. Total operating expenses fell to $2.7 million from $4.1 million, reflecting lower research and development and general and administrative costs.
At June 30, 2026, Allarity held $17.0 million in cash and $10.0 million in restricted cash, with total assets of $32.1 million. Total liabilities rose to $28.6 million, driven largely by a new short-term promissory note of $20.9 million, reducing stockholders’ equity to $3.5 million. Operationally, the company completed a Phase 3-ready stenoparib manufacturing campaign, obtained CLIA certification for its in-house DRP companion diagnostic laboratory, and highlighted a newly granted U.S. patent extending stenoparib DRP exclusivity into 2042.
Allarity Therapeutics, Inc., a clinical-stage oncology company, reported continued operating losses but a strengthened cash position for the quarter and six months ended June 30, 2026. Total assets were $32.1 million, up from $18.3 million at year-end, driven mainly by cash and restricted cash of $26.9 million.
The company recorded a six‑month net loss of $6.2 million (basic and diluted loss per share $0.39) on minimal revenue of $0.025 million from DRP testing services. Operating expenses declined year over year, with research and development at $2.6 million and general and administrative at $2.7 million for the six‑month period, reflecting lower clinical and legal costs.
To fund operations, Allarity completed a $20.0 million dual‑note financing with Streeterville Capital and established a $6.0 million equity line of credit with Tumim Stone Capital. Total liabilities increased to $28.6 million, and stockholders’ equity fell to $3.5 million. Management states existing cash and restricted cash are expected to fund operations for at least twelve months from the financial statement issuance date.
Allarity Therapeutics, Inc. reported results from its annual stockholder meeting and announced a newly granted U.S. patent. Stockholders elected Jesper Hoiland as director and ratified Wolf & Company, P.C. as auditor. They also approved an increase in shares available under the 2021 Equity Incentive Plan and an advisory vote on executive compensation.
Holders approved issuing common stock under a January 2026 Common Stock Purchase Agreement with Tumim Stone Capital LLC above the exchange cap, while an amendment to limit certain officer liability did not pass. Separately, the USPTO granted a key U.S. patent for Allarity’s stenoparib-specific DRP companion diagnostic, with a term extending into April 2042, supporting the company’s personalized oncology strategy.
Allarity Therapeutics, Inc. filed an 8-K to share a press release about presenting a Trial-in-Progress poster on its ongoing Phase 2 trial of stenoparib in advanced platinum-resistant or platinum-ineligible ovarian cancer at the ESMO Gynaecological Cancers Congress 2026 in Copenhagen.
The poster explains the scientific background, study design, and clinical rationale, but does not include new clinical data. Allarity highlights prior Phase 2 experience showing durable clinical benefit in heavily pretreated ovarian cancer patients and its DRP® companion diagnostic strategy to select patients most likely to benefit from stenoparib.
Allarity Therapeutics, Inc. entered into an amended and restated Management Services Agreement with Ljungaskog Consulting AB, the firm of CEO Thomas H. Jensen, effective June 1, 2026. The agreement fully replaces the prior 2024 management services arrangement.
The consultant’s 2026 base compensation will be paid 80% in Swedish Krona and 20% in U.S. dollars, equal to SEK 6,000,000 and US$163,043. The prior one-time US$100,000 signing bonus is removed. Annual bonus metrics are to be set each year, with any bonus capped at 60% of fees paid and, if earned, payable by March 15 following year-end.
For a termination by the company for convenience, the notice period increases from 15 to 30 days and the consultant becomes eligible for a termination payment equal to 12 months of the monthly fee, in addition to accrued amounts, subject to conditions such as a release and cooperation. Upon a termination by the consultant for Good Reason, severance increases from nine months to 12 months of the monthly fee on similar conditions. The agreement also adds provisions addressing Sections 409A and 280G of the U.S. Internal Revenue Code when applicable.
Allarity Therapeutics, Inc. reported a net loss of $2.8 million for the three months ended March 31, 2026, on minimal license revenue of $0.025 million. Research and development expenses were $1.3 million and general and administrative expenses were $1.4 million, both modestly lower than a year earlier.
Cash, cash equivalents and restricted cash totaled $29.8 million as of March 31, 2026, supported by $20.0 million of new promissory notes and a $6.0 million common stock purchase agreement with Tumim Stone Capital LLC. The company repurchased 264,000 shares for $0.3 million under its share repurchase plans and believes existing capital will fund operations for at least the next twelve months while it advances its lead cancer candidate stenoparib.
Jensen Thomas reported acquisition or exercise transactions in this Form 4 filing.
Allarity Therapeutics CEO Thomas Jensen received an equity grant of 200,000 shares of common stock as a compensation award. These shares are in the form of restricted stock units granted under the company’s Amended and Restated 2021 Equity Incentive Plan and were awarded at no cash cost per share.
The RSUs will vest in three equal annual installments on the first, second, and third anniversaries of the January 28, 2026 grant date, if he continues his relationship with the company through each vesting date. After this grant, Jensen holds 596,734 common shares directly.
Allarity Therapeutics director Jesper Hoeiland was granted equity compensation. The Form 4 reports an acquisition of 25,000 shares of Common Stock at a stated price of $0.00 per share, bringing his direct holdings to 25,000 shares after the transaction.
According to a footnote, these shares reflect restricted stock units granted pursuant to Allarity Therapeutics, Inc.'s Amended and Restated 2021 Equity Incentive Plan, which vested in full on the grant date. This filing reflects a compensation-related award rather than an open-market trade.
Allarity Therapeutics filed an initial ownership report for director Jesper Hoeiland. This Form 3 identifies Hoeiland as a director of Allarity Therapeutics, Inc. and serves as his initial statement of beneficial ownership in the company’s securities. The filing does not list any reportable transactions or derivative positions at this time.